INFLARX N.V. EO 0,12/ NL0012661870 /
8/30/2024 4:06:28 PM | Chg. +0.0450 | Volume | Bid9:56:43 PM | Ask9:56:43 PM | High | Low |
---|---|---|---|---|---|---|
1.4200EUR | +3.27% | 200 Turnover: 297.6000 |
-Bid Size: - | -Ask Size: - | 1.4880 | 1.4200 |
GlobeNewswire
8/8
InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
7/30
InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Huma...
GlobeNewswire
6/24
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel ...
GlobeNewswire
5/21
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Poten...
GlobeNewswire
4/30
InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2...
GlobeNewswire
4/24
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
GlobeNewswire
4/16
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Dir...
GlobeNewswire
3/19
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
GlobeNewswire
1/25
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Acc...
GlobeNewswire
1/4
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with...
GlobeNewswire
11/6/2023
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
GlobeNewswire
11/1/2023
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire
9/11/2023
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C...
GlobeNewswire
8/30/2023
InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill ...
GlobeNewswire
3/17/2022
InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hi...
GlobeNewswire
3/8/2022
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentat...
GlobeNewswire
2/28/2022
InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa